Karin Innes
Partner
Karin Innes is a partner in our Melbourne biotechnology team.
Karin’s technical knowledge covers a range of technologies including stem cells, immunology, CAR-T/DC cell technology, antibodies, aptamers, medical devices, diagnostics, PCR technology, women’s health, gene therapy and virology. She advises clients in all stages of patent procurement, patent strategy, due diligence and freedom to operate, and is passionate about working with her clients to align their IP with their commercial strategy. She has also worked on a number of opposition cases before the Australian and New Zealand patent offices, and has assisted clients in the preparation of their prospectus for listing on the Australia stock exchange, as well as in the preparation of ASX announcements. Karin represented Ganymed Pharmaceuticals in the successful patent prosecution case before the IP Office of New Zealand; resulting in FB Rice winning “New Zealand Impact Case of the Year” at the Managing IP Asia Pacific Awards 2022. Karin has been endorsed in the IAM Prosecution recommended list each year since 2020.
Industry:
Technical Group:
Read Karin's full bio
Education
- PhD in Medical Biology, The Walter and Elisa Hall Institute for Medical Research
- Bachelor of Science (Hons), Microbiology and Biochemistry, The University of Melbourne
- Diploma Intellectual Property Practice, Melbourne
Industry Expertise
- Women's health technology
- Diagnostics
- Stem cells and cell therapies
- Immunology, including antibodies, aptamers, immunoglobulin-like molecules, CAR-T, CAR-DC
- Virology, including mRNA vaccine technologies and gene therapy
Professional Affiliations
- Board member - Trans-Tasman IP Attorneys Board
- Fellow - The Institute of Patent and Trade Mark Attorneys of Australia (IPTA)
- Committee member - Intellectual Property Society of Australia and New Zealand (IPSANZ)
- Member - AusBiotech